GlassScriptPhysician profile
Rahim Raoufi
NPI 1356327597
$101,534.22
in general payments reported to CMS, 2019-2025
26 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $13K · 2021: $16K · 2022: $24K · 2023: $4,188 · 2024: $9,048 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,500 · Food and Beverage: $4,456 · Travel and Lodging: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,500.00 |
| Food and Beverage | $4,455.70 |
| Travel and Lodging | $710.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $65,829.39 | 2019-2025 | Epclusa |
| Abbvie INC. | $32,885.65 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $655.22 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $334.12 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $244.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $240.16 | 2020-2025 | Resolution 360 Clip, Cinchpad, Dreamtome Rx 49 |
| Pfizer INC. | $152.82 | 2023-2025 | |
| Celgene Corporation | $144.42 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $133.05 | 2020-2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $121.31 | 2023-2024 | Dupixent |
| Genzyme Corporation | $116.15 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.74 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $98.16 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $90.87 | 2023-2024 | Andexxa |
| Janssen Biotech, INC. | $84.69 | 2021-2025 | Stelara, Simponi Aria, Tremfya |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $81.45 | 2024 | Omvoh |
| Redhill Biopharma INC. | $73.89 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $22.61 | 2022 | |
| Albireo Pharma, INC. | $17.91 | 2024 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $17.17 | 2021 | |
| Qol Medical, LLC | $16.94 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $16.24 | 2024 | |
| Lucid Diagnostics INC. | $15.26 | 2022 | |
| Medtronic, INC. | $15.08 | 2024 | Gi Genius |
| Allergan, INC. | $11.90 | 2019 | |
| Shionogi INC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahim Raoufi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.